PCOS

PCOS is fundamentally a condition driven by excess estrogen, not an excess of androgens as mainstream medicine claims. 2 Ray Peat argued that the elevated androgens characteristic of the syndrome are a defensive adaptation; when the body is shocked by a dose of estrogen and lacks the resilience to produce sufficient progesterone, it responds by increasing androgen production. 1 This framing inverts the standard "hyperandrogenic anovulation" model, identifying a progesterone deficiency as the core failure that allows the pathology to proceed. 2 Georgi Dinkov has pointed out the contradiction in official descriptions, noting that while the condition is labeled hyperandrogenic, medical literature also admits to an incredibly high production of estrogen and a near-universal presence of central obesity, which is indicative of high cortisol. 2

The mechanism of estrogen-driven ovarian damage involves a direct induction of the syndrome. Animal studies demonstrate that administering estradiol valerate—the same estrogen ester used in most contraceptive pills—reliably produces PCOS in just a few weeks. 2 Dinkov has highlighted that the doses used in these experiments are often lower than what women take daily for years, suggesting a direct link between the epidemic of PCOS and the widespread use of hormonal contraceptives. 4 Peat detailed a specific neurological pathway where estrogen induces the production of nerve growth factor in the ovary, causing an invasion of sympathetic nerves. 8 This sympathetic overgrowth suppresses the number and activity of mast cells, which are required for follicles to rupture, thereby preventing ovulation and creating the cystic morphology. 8

The metabolic context for this estrogen dominance is a state of low thyroid function and stress. The pituitary hormones luteinizing hormone (LH) and follicle stimulating hormone (FSH) have estrogen-like actions and are increased by a perceived energy deficiency, which is fundamentally a problem of low thyroid-driven oxidative metabolism. 9 Prolactin, another pituitary hormone elevated in stress, inhibits ovarian progesterone production and reduces the cell's ability to consume oxygen, pushing metabolism toward glycolysis and lactic acid production instead of oxidative energy. 9 Dinkov has noted that the largest studies on PCOS found elevated DHEA-S, an adrenal androgen, rather than DHT, tying the condition to excessive adrenal activity that kicks in when thyroid and gonadal function are insufficient. 6 This explains why PCOS is considered the female analog of premature male pattern baldness, as both conditions share a hormonal environment of low thyroid, high estrogen, and high stress hormones. 2

Therapeutic approaches consistent with this model focus on reducing estrogen's effects and restoring oxidative metabolism. Peat emphasized that anti-estrogenic interventions are highly therapeutic. 3 Dinkov has reported that aromatase inhibitors can stop PCOS, and that high doses of progesterone, aspirin, or vitamin E can be helpful. 7 He has also observed that cyproheptadine, a drug with potent estrogen receptor alpha-inhibiting effects, has fully stopped PCOS and reversed fibroid cystic effects in some cases. 7 However, the most systemic approach targets the root cause: thyroid supplementation to calm the pituitary and reduce the stress response, rather than chasing individual stress biomarkers. 6 Danny Roddy has summarized that the cell's inability to produce oxidative energy and its shift toward glycolytic cell division under estrogen's influence is the fundamental pathology, making the restoration of proper metabolic function the central therapeutic goal. 9